ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ...
TRANSCRIPT
![Page 1: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/1.jpg)
ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ
ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗ
Μ.Β.Παπαβασιλείου
Καρδιολόγος FESC
Διευθύντρια
Σισμανόγλειον ΓΝΑ
Clinical Hypertension Specialist ESH
![Page 2: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/2.jpg)
ΔΗΛΩΣΗ ΣΥΜΦΕΡΟΝΤΩΝ
ΚΑΝΕΝΑ ΣΥΜΦΕΡΟΝ
![Page 3: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/3.jpg)
Rheumatic disease is not a single
disorder
Rheumatic diseases encompass more
than 200 different diseases which
span from various types of arthritis to
osteoporosis and on to systemic
connective tissue diseases
Any organ system may be affected
EULAR
Rheumatology (Greek ρεύμα, rheuma, flowing current)
![Page 4: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/4.jpg)
Basic Classification of the Rheumatic Diseases
A) Inflammatory Rheumatic Diseases
Diffuse connective tissue diseases• Rheumatoid arthritis (RA)
• Systemic lupus erythematosus(SLE)
• Systemic sclerosis (SS)
• Polymyositis (PM)-Dermatomyositis(DM)
• Sjőgren´s syndrome
• Vasculitides
Arthritis associated with spondylitis
(Spondylarthritis sero-negative)• Ankylosing Spondylitis (AS)
• Psoriatic Arthritis (PsA)
• Reactive Arthritis (ReA) (Reiter’s syndrome)
• Enteropatic arthritis –A.associated with inflammatory bowel Diseases
B. Degenerative Joint Disease (osteoarthritis)
C. Metabolic and Endocrine Diseases associated with rheumatic states(crystal induced arthropathy-gout, pseudogout)
D. Extraarticular disorders (low back pain, fibromyalgia)
E. Rheumatic syndrome associated with infectious agents
F. Bone and cartilage disorders (osteoporosis)
G. Others
![Page 5: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/5.jpg)
Prevalence of autoimmune diseases:
The American Autoimmune Related Diseases Association, Inc
While the National Institutes of Health estimate that up to 23.5 million Americans suffer from autoimmune diseases,
AARDA puts the estimate at 50 million
Autoimmune disease is one of the top 10 leading causes of death in female children and women in all age
groups up to 64 years of age
Angylosing spondylitis f/m:1/4
Prevalence of rheumatic diseases
in central Greece BMC 2010
Osteoarthritis
![Page 6: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/6.jpg)
The estimated prevalence of gout
across the world
Kuo, C.-F. et al.
Nat. Rev. Rheumatol. 2015
Prevalence of gout
in central Greece 4.71% f/m:0/8
BMC 2010
![Page 7: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/7.jpg)
Image via ChildHealth-Explanation.com
Environmental toxins are a
major cause of autoimmune
disease
smoking
![Page 8: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/8.jpg)
![Page 9: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/9.jpg)
Atherothrombosis in the rheumatic diseases
Justin C. Mason, and Peter Libby Eur Heart J 2015;36:482-489
![Page 10: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/10.jpg)
Pathogenesis of atherosclerosis in inflammatory rheumatic diseases
Justin C. Mason, and Peter Libby Eur Heart J 2015;36:482-489
Type I interferons
Immune dysregulation
and systemic
inflammation
![Page 11: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/11.jpg)
Natural history of RA development
Holers VM Rheum Dis Clin North Am. 2014
Insights from Populations At-Risk for the Future
Development of Classified RA
Preclinical rheumatic disease
atherosclerosisCirculating disease-specific autoantibodies
Anti-citrullinated protein/peptide antibodies (ACPA)
inflammation is an important promoter of premature atherosclerosis in RA patients.
smoking
![Page 12: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/12.jpg)
Systemic
Diseases of
Connective
Tissue
![Page 13: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/13.jpg)
Schematic representation of the adventitious
"outside-in" paradigm in CVD
Daniel N. et al Hypertension. 2016
systemic inflammation
and endothelial
dysfunction
Reduction of NO production
in endothelial cells leads to
vasoconstriction, increased
production of ET-1 and
platelet activation
![Page 14: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/14.jpg)
In RA, primary site of inflammation is synovial tissue, from which cytokines can be released into systemic circulation
Naveed Sattar et al. Circulation. 2003
How do
cytokines operate to
promote vascular
disease at the
molecular
level, and in which
tissues?
The answer likely
lies in the
pleiotropic functions
of cytokines,
because in addition
to their
role in regulating
immune responses,
cytokines mediate
numerous metabolic
effects
![Page 15: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/15.jpg)
Relationship between changes in inflammatory and lipid parameters
Ernest Choy et al. Rheumatology 2014;53:2143-2154
HS-cTnT
ESR>60mm/h
![Page 16: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/16.jpg)
Ang II in inflammation, immunity and RA
Chang Y, Wei W.
Clin Exp Immunol. 2015
The roles of Ang II on innate and adaptive immunity.
Ang II via AT1R signalling in immune cells contributes to the inflammatory
responses and activation of the immune system.
CRP is able to
up-regulate the
expression
of AT1 receptors
thus activating the
RAS
![Page 17: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/17.jpg)
Comorbidities
![Page 18: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/18.jpg)
Traditional and nontraditional risk factors
for CVD in RA
Amaya-Amaya J, et al Biomed Res Int. 2014;2014
![Page 19: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/19.jpg)
Prevalence of evaluated comorbidities in the 3920 patients with RA
Maxime Dougados et al. Ann Rheum Dis 2014;73:62-68
COMORA: international, cross-sectional study
![Page 20: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/20.jpg)
List of diseases, which are considered in 39 different
multimorbidity indices
Claudia Diederichs et al. J Gerontol A Biol Sci Med Sci 2011-311
Meta-analysis
in older people
![Page 21: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/21.jpg)
Annemans, et al. Ann Rheum Dis 2008;67:960-966.
UK population German population
Comorbid conditions in two European
populations of patients with gout
![Page 22: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/22.jpg)
ORs of individual studies and of pooled data for the association between
MetS and RAThe Risk of MetS in Patients with RA: A Meta-Analysis of Observational Studies
Jianming Zhang et al PLoS One. 2013;8(10):e78151.
![Page 23: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/23.jpg)
S A Karvounaris, et al. Ann Rheum Dis. 2007
Correlation of DAS28 with the number of MetS
components present
N=200 RA
400 C
M Age 63y
Mediterranean
patients
![Page 24: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/24.jpg)
Key soluble biomarkers that are associated with different stages of the atherosclerotic pathway in the MetS and RA
Lukasz Kozera et al. Rheumatology 2011;50:1944-1954
SAA: serum amyloid A;
PAI-1: plasminogen activator inhibitor-1.
![Page 25: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/25.jpg)
Distribution of BMI categories among an Italian cohort
of adult autoimmune disease patients
Gremese,E et al Front Immunol. 2014
![Page 26: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/26.jpg)
Cytokine-related link between obesity and chronic inflammation
Obesity is associated with increased levels of leptin, PAI-1, IL-6 and TNF-α
Anna Russolillo et al. Rheumatology 2013;52:62-67
![Page 27: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/27.jpg)
Leptin and homocysteine distribution according to HTN
status and adjusted probability of HTN
Manavathongchai S, et al Rheumatol. 2013
![Page 28: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/28.jpg)
Physical inactivity is most common among adults who have
both heart disease and arthritis
Physical inactivity among adults age ≥18 years, by arthritis and heart disease status
Data Source: Behavioral Risk Factor Surveillance System, United States, 2005 and 2007; as printed in:
Bolen J, Murphy L, Greenlund K, , Helmick CG, Hootman J, Brady TJ, Langmaid G, Keenan N. Arthritis as
a potential barrier to physical activity among adults with heart disease — United States, 2005 and
2007. MMWR 2009;58(7):165-169.
![Page 29: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/29.jpg)
Venn diagram showing the number of overlapping
genes between psoriasis and its comorbidities
Sundarrajan S, et al PLOS ONE 2016
![Page 30: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/30.jpg)
ATHEROSCLEROSIS
![Page 31: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/31.jpg)
Atherosclerosis and chronic inflammatory disease
Katharina Andrea Schuett et al
Front Immunol. 2015;6:591.
descending
aorta severe inflammatory RA
Pasceri V Circulation 1999
![Page 32: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/32.jpg)
Elaine Husni Cleaveland clinic 2010
![Page 33: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/33.jpg)
Proportion of patients with carotid plaque according to ESR AUC category and the number of conventional CV risk
Churl Hyun Im et al. Rheumatology 2015;54:808-815
AUC: area under the curve
RA patients
![Page 34: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/34.jpg)
Multivariable regression analysis with identified
covariables associated with cIMT
van Breukelen—van der Stoep DF, et al PLOS ONE 2015
![Page 35: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/35.jpg)
PWV is high in SLE patients and correlates with SBP
Sacre K, et al PLOS ONE 2014
Increased Arterial Stiffness in SLE Patients at Low Risk for CVD:
A Cross-Sectional Controlled Study
![Page 36: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/36.jpg)
Assessment of aortic stiffness B: 2D guided M-mode images of the mid descending
thoracic aorta in a 39 year old SLE patient with aortic
stiffness based on minimal change in aortic diameters
during systole and diastole
Roldan PC, et al Rheumatology (Sunnyvale). 2014
![Page 37: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/37.jpg)
CVD
![Page 38: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/38.jpg)
conventional risk
factors
![Page 39: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/39.jpg)
Meta-analysis of the influence of diverse chronic
inflammatory conditions on multiple CV (stroke, CAD) and type 2 DM outcomes
Alex Dregan et al. Circulation. 2014;130:837-844
![Page 40: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/40.jpg)
CV events prior to or early after diagnosis of SLEin the systemic lupus international collaborating clinics cohort
Multivariable logistic regression for the outcome of early MI
M B Urowitz et al. Lupus Sci Med 2016;3:e000143
![Page 41: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/41.jpg)
The excess risk of CVD in RA seems to be comparable to the risk of CVD
conferred by DM2, suggesting that RA is also a CHD equivalent.
![Page 42: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/42.jpg)
Cause‐Specific Mortality in Male US
Veterans With RA
England BR, et al Arthritis Care Res (Hoboken). 2016
![Page 43: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/43.jpg)
![Page 44: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/44.jpg)
Risk of CV mortality in patients with RA:
A meta‐analysis of observational studies
Aviña-Zubieta JA, et al Arthritis Rheum. 2008
N=111758
50% increased risk of
CVD death in patients with RA
![Page 45: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/45.jpg)
HYPERTENSION
![Page 46: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/46.jpg)
Hypertension pathways in RA
V. F. Panoulas et al. Rheumatology 2008;47:1286-1298
![Page 47: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/47.jpg)
Immune
activation caused
by vascular
oxidation
promotes fibrosis
and HTN
Wu J, Saleh MA, et al
J Clin Invest. 2016
![Page 48: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/48.jpg)
CV risks among rheumatic diseases.Prevalence of CV risk factors in RA, gout, OA, CTD,
PMR and CPS
Inger L. Meek et al. Rheumatology 2013;52:210-216
ORs in comparison with the general population.
chronic localized or generalized pain syndromes (CPSs
prevalence of HTN is estimated to 52–73%
![Page 49: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/49.jpg)
Chronic Disease Risk Factors are Common
among Adults with Arthritis
Data source: National Health Interview Survey, 2007; as printed in: Murphy L, Bolen J, Helmick CG, Brady
TJ. Comorbidities Are Very Common Among People With Arthritis. Poster 43. 20th National Conference on
Chronic Disease Prevention and Control, CDC February 2009.
![Page 50: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/50.jpg)
17/2/2017
Prevalence of HTN, hypercholesterolemia and AMI in the CIRD cohort
(Exp) and in the unexposed matched cohort (Unexp)chronic inflammatory rheumatic diseases (CIRD)
Castañeda S et al
Arthritis Rheum. 2015
N=2234 Exp
N=677 Unexp
CARMA ProjectHTN
HTN
![Page 51: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/51.jpg)
Prevalence of BP levels under the studied conditions.
in the overall RA cohort as well as in the general population
of the ATTICA study
Protogerou AD, et al
Arthritis Res Ther. 2013
N=242
RA patients
![Page 52: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/52.jpg)
Relative risk of MI in hypertensive RA patients versus those without
HTN using random effect model
Baghdadi LR, et al. PLOS ONE 2015
The Impact of Traditional CV Risk Factors on CV Outcomes in Patients with RA:
A Systematic Review and Meta-Analysis
![Page 53: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/53.jpg)
Frequency of RA in strata defined by the quartiles of total
daily sodium intake and smoking exposure
Salgado E, et al
Medicine (Baltimore). 2015
![Page 54: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/54.jpg)
Control of CV risk factors: proportion of patients in whom therapeutic
goals were met for treatment of HTN, dyslipidemia and diabetes
Chung CP, et al Semin Arthritis Rheum. 2012
N=197 RA
N=274 controls
![Page 55: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/55.jpg)
Clusters of Disease in VA• National VHA data used to identify cohort aged 55 to 64
years in 2000 (N=741,847)
• ICD-9 codes used to identify presence of 11 chronic
conditions and mutually exclusive clusters created
Condition N (%) 5-Year
Mortality %
Hypertension + Diabetes 47,568 (6.4) 6.3
IHD + Hypertension 28,154 (3.8) 6.3
Hypertension + Osteoarthritis 23,692 (3.2) 2.9
IHD + Hypertension + Diabetes 19,161 (2.6) 11.1
Hypertension + COPD 11,883 (1.6) 12.2
Hypertension + Diabetes + Osteoarthritis 9,136 (1.2) 5.3
![Page 56: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/56.jpg)
Feig DI, et al.
N Engl J Med 2008
Uric acid mediated hypertension
![Page 57: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/57.jpg)
Grayson PC, et al. Arthritis Care Res (Hoboken) 2011;63(1):102-10.
Hyperuricaemia is related to incident HTN
Hyperuricaemia is associated with an increased risk for incident
HTN, independent of traditional HTN risk factors
Decreased Increased
Risk of hypertension
0 1 3
![Page 58: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/58.jpg)
Chen JH, et al. Arthritis Rheum 2009;61(2):225-232.
HRs of hyperuricaemia on CV mortality
and all-cause mortality
(1)
(2)
CV mortality
all-cause mortality
![Page 59: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/59.jpg)
Gout and CVD
Prevalence of CV risk factors in rheumatic and gout patients
and a sample of the general population
Adapted from: Meek IL, et al. Rheumatology 2013;52(1):210-6.
0
10
20
30
40
50
60
70
100
Hypertension Overweight Obesity Current
smoking
Pati
en
ts (
%)
66%
56%
72%
28%
17%26%
21%
62%
General population (n=4523)
Rheumatic outpatients (n=1233)*
*
*
*
* p<0.05
83%*
80
90
94%*
*48%
26%
Gout patients (n=129)
ADENURIC® is a trademark of Teijin Limited, Tokyo, Japan.
![Page 60: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/60.jpg)
KIDNEY
![Page 61: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/61.jpg)
Renal manifestations of systemic diseases commonly
seen by rheumatologists
Anders and Vielhauer Arthritis Research & Therapy 2011
![Page 62: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/62.jpg)
(15-50%)
30-50% of patients will have clinical manifestations of renal
disease at the time of diagnosis: deposition of circulating immune complexes
Tubular abnormalities (60-80%)
(100%)
![Page 63: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/63.jpg)
?
![Page 64: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/64.jpg)
Aetna Database – Cohort-wide Incidence Rates(Events per 1,000 Patient-years, Unadjusted)
139
1 0.3
85
3
38
8
0
20
40
60
80
100
120
140
160
Even
ts/1
,000 P
Y
N=40594 RA: leflunomide, methotrexate
or another DMARD, including biologic
DMARDs
RA prevalence 0.63%
74% women
Age:51–64 y
81% on monotherapy
or 2 drug
combinations
![Page 65: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/65.jpg)
Mechanisms through which drugs used in RA affect BP
V. F. Panoulas et al. Rheumatology 2008;47:1286-1298
PG: prostaglandin
Lef: leflunomide
![Page 66: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/66.jpg)
Anti-rheumatic drugs and CV risk
Justin C. Mason, and Peter Libby Eur Heart J 2015
(5.0 mm Hg )
![Page 67: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/67.jpg)
Predictive factors for HTN in CIRD subjects
Singwe-Ngandeu M et al Open Journal of Rheumatology and Autoimmune Diseases 2016
Chronic inflammatory rheumatic diseases (CIRD
![Page 68: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/68.jpg)
Nonsteroidal anti-inflammatory drugs antagonized the antihypertensive
effect of b-blockers (BP elevation, 6.2 mm Hg) more than did vasodilators and diuretics
RAAS-b 20mmHg
CaCBs
![Page 69: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/69.jpg)
![Page 70: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/70.jpg)
Mortality
Emmert Roberts et al. Ann Rheum Dis 2016;75:552-559
Paracetamol: not as safe as we thought?
A systematic literature review of observational studies
![Page 71: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/71.jpg)
![Page 72: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/72.jpg)
Current Pharmaceutical Design
2012;18(11):1502-11
Therapeutic Advances Musculoskeletal Disease
![Page 73: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/73.jpg)
![Page 74: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/74.jpg)
Predicted probability of rapid IMT progression, according to the ESR,
stratified by: (A) use of methotrexate; (B) use of anti-TNF agents
del Rincón I, et al Ann Rheum Dis. 2015
erythrocyte sedimentation rate (ESR),
![Page 75: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/75.jpg)
Typical PET/CT images before and after anti-TNF-α therapy.
Kaisa M. Mäki-Petäjä et al.
Circulation. 2012;126:2473-2480
Following anti-TNF-
α therapy, there
was a significant
reduction in mean
aortic TBRmax
The proportion of hot slices
was reduced (from 49.5±28.9
to 33.3±27.1%, P=0.03)
![Page 76: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/76.jpg)
ETAN: etanercept (soluble TNF-a receptor inhibitor)
INFLIX : infliximal (TNF-a inhibitor)
![Page 77: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/77.jpg)
![Page 78: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/78.jpg)
Risks of CKD among RA patients treated with medications
Chiu HY, et al PLOS ONE 2015
![Page 79: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/79.jpg)
Managing Hypertensive Patients With
Gout Who Take Thiazide
Joel Handler The Journal of Clinical Hypertension 2010
![Page 80: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/80.jpg)
Effect of Allopurinol on Blood Pressure: A Systematic Review and Meta‐Analysis
Forest plot showing the effect of allopurinol on SBP
Agarwal V et al The Journal of Clinical Hypertension 2012
![Page 81: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/81.jpg)
Effect of Allopurinol on Blood Pressure: A Systematic Review and Meta‐Analysis
Forest plot showing the effect of allopurinol on DBP
Agarwal V et al The Journal of Clinical Hypertension 2012
![Page 82: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/82.jpg)
Forest plots illustrating the effect of different allopurinol cohorts on outcome
Rachael L. MacIsaac et al. Hypertension. 2016;67:535-540
>65 y
with HTN
N=2032 allopurinol-exposed
2032 matched nonexposed
rates of stroke
and cardiac events
![Page 83: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/83.jpg)
Guidelines
![Page 84: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/84.jpg)
RisksBenefits
Benefits of early DMARDs outweigh their risks
Yes DMARDs are safe when monitored regularly
E
A
R
L
Y
![Page 85: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/85.jpg)
For all patients with RA
as evidence on the increased
CVD risk in patients
who are in the early stages of
RA, patients with a recent RA
diagnosis and patients without
extra-articular manifestations
EULAR recommendations for CVD risk management in patients with RA
and other forms of inflammatory joint disorders: 2015/2016 update
![Page 86: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/86.jpg)
EULAR 2016
![Page 87: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/87.jpg)
EULAR recommendations 2016
for gout: diagnosis
Zhang W, et al. Ann Rheum Dis 2006;65(10):1301-1311.
10
Risk factors and associated co-morbidity can be assessed
during the diagnosis of gout, including features of the metabolic
syndrome (obesity, hyperglycaemia, hyperlipidaemia, hypertension).
![Page 88: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/88.jpg)
![Page 89: ΡΕΥΜΑΤΙΚΕΣ ΝΟΣΟΙ ΚΑΙ ΑΡΤΗΡΙΑΚΗ ΥΠΕΡΤΑΣΗstatic.livemedia.gr/hcs2/documents/al19480_us41... · Katharina Andrea Schuett et al Front Immunol. 2015;6:591](https://reader033.vdocuments.pub/reader033/viewer/2022053017/5f1b6d441540824c95301368/html5/thumbnails/89.jpg)
The Big Bang